Why Your Anti-Inflammatory Shot Might Be Too Strong: New Study Reveals How to Stop Disease Without Killing Good Cells
Scientists find a way to target only the bad inflammation while saving the healing parts of your immune system.
We all deal with inflammation. It is the body's natural alarm system. Sometimes you need that alarm to go off. Think of it like salt in a soup. You need a pinch to make it taste alive. If you dump too much salt into the pot, however, you ruin the whole meal. Your immune system works the same way. It has a molecule called interleukin-6 or IL-6. Researchers at the PMI Exzellenzcluster Präzisionsmedizin für chronische Entzündungserkrankungen describe this molecule as contradictory. It helps your liver regenerate after an injury and protects you from infections. At the same time, it can drive chronic inflammation in conditions like rheumatoid arthritis or inflammatory bowel disease. A recent review in Nature Reviews Drug Discovery suggests we might be throwing the baby out with the bathwater when treating these conditions.
Currently, the standard treatment involves a heavy-duty artillery. Drugs like tocilizumab and sarilumab work by blocking the IL-6 receptor across the board. They turn off the signal to stop the pain and swelling. This works for many people. However, this blanket approach comes with a price. Because these drugs block both the harmful and the helpful signals, patients sometimes face increased susceptibility to infections and changes in blood lipid levels. In some cases, there are even more serious complications. A team led by Professor Stefan Rose-John from the Institute of Biochemistry at Kiel University along with Dr. Georg Wätzig from CONARIS Research Institute AG in Kiel and Professor Stefan Schreiber from the Department of Internal Medicine I at University Hospital Schleswig-Holstein wanted to find a smarter way to cook.
These experts realized that the problem lies in the fact that IL-6 works through two distinct pathways. To understand this, you have to look at how the molecule travels. In one route, known as "classic" signaling, IL-6 binds to a receptor found only on a few specific cells. These cells include certain types of immune cells and the liver cells responsible for regeneration. This pathway is predominantly protective. It supports tissue repair and helps defend the body against infections. In the second route, called trans-signaling, the IL-6 receptor must be present in a soluble form in the blood. This soluble receptor is produced mainly by a process called proteolysis. This soluble complex can bind IL-6 and travel to any cell in the body because every cell carries a secondary receptor called glycoprotein 130. This trans-signaling is the one that drives the chronic inflammation causing you pain.
The breakthrough here is that the antibody therapies available today cannot distinguish between these two routes. They attack the IL-6 receptor indiscriminately. Professor Rose-John noted that for a long time IL-6 was viewed primarily as a driver of inflammation. Only with their discovery did it become clear that its protective and harmful effects should, in principle, be separable. The new drug they are focusing on is olamkicept. This substance was the result of years of development work. It works by selectively capturing the soluble receptor complex. This complex is responsible for the disease-causing trans-signaling. Importantly, it leaves the protective classic signaling untouched. Dr. Wätzig emphasized that it is not enough to simply block IL-6 less strongly. The key was finding a molecular target where only the disease-causing pathway can be interrupted.
The difference this makes is visible in the research data. In a randomized clinical trial involving patients with ulcerative colitis, 58.6 percent of the patients responded to olamkicept therapy. This response rate is significantly higher than the 34.5 percent response rate seen with the placebo. Perhaps more importantly, the side effects that are common with other IL-6 therapies did not occur during this trial. Animal studies back this up with a clear pattern. When researchers inhibited only trans-signaling, the protective effect of IL-6 was preserved. The disease usually improved just as much as it would with complete IL-6 blockade. In some cases, the improvement was even greater. In a sepsis model, for instance, inhibiting trans-signaling within a certain dose range saved all mice from death by severe sepsis. Complete blockade, by contrast, offered no advantage over the placebo group.
This approach represents a shift from a blanket approach to precision medicine. Together with an international partner, olamkicept is now set to enter decisive phase 3 clinical testing. The authors believe this is a model for the future of inflammation medicine. The principle of switching off only the disease-causing pathway of a messenger while preserving the protective one could, in principle, be transferred to other messengers as well. This could mean more effective therapies with fewer side effects for chronic inflammatory diseases. It acts precisely where a disease arises without disturbing the rest of the body's harmony. It is a much more refined way to manage our health than trying to blast everything with a sledgehammer.
First reported by Medical Xpress.
More in Health & Nutrition
- Long-term opioid use fails to alleviate chronic back pain, Northwestern University study suggests
Researchers identified distinct brain activity patterns and molecular markers that may guide future treatments for pain management and opioid tapering.
- Human tau seeds trigger disease-specific shapes in mouse brains, new study finds
Study in Nature shows that injectable human tau aggregates from Alzheimer’s and corticobasal degeneration template their 3D folds onto mouse tau, supporting the prion-like seeding model.
- Menopause Largely Missing from Electronic Health Records Despite Its Health Impact
study of nearly 240,000 women finds only 12% of electronic records include menopause status, even though over half reported being in transition.